Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Imiglucerase
Drug ID BADD_D01138
Description Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues.
Indications and Usage For the treatment of Gaucher's disease (deficiency in glucocerebrosidase)
Marketing Status approved
ATC Code A16AB02
DrugBank ID DB00053
KEGG ID D03020
MeSH ID C090568
PubChem ID Not Available
TTD Drug ID D0QW9H
NDC Product Code 67643-0020; 58468-4663
UNII Q6U6J48BWY
Synonyms imiglucerase | Cerezyme
Chemical Information
Molecular Formula Not Available
CAS Registry Number 154248-97-2
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abscess sterile08.01.05.008--Not Available
Angioedema23.04.01.001; 10.01.05.009; 22.04.02.008--Not Available
Back pain15.03.04.005--
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.009--Not Available
Chills15.05.03.016; 08.01.09.001--
Cough22.02.03.001--
Cyanosis23.06.04.005; 02.11.04.004; 24.03.01.007; 22.02.02.007--
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dyspnoea02.11.05.003; 22.02.01.004--
Fatigue08.01.01.002--
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Headache17.14.01.001--
Hypotension24.06.03.002--
Nausea07.01.07.001--
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Tachycardia02.03.02.007--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vomiting07.01.07.003--
Injection site discomfort12.07.03.019; 08.02.03.018--Not Available
Vessel puncture site pain12.07.04.005; 08.02.04.005--Not Available
Vessel puncture site swelling08.02.04.006; 12.07.04.007--Not Available
The 1th Page    1    Total 1 Pages